Berkshire’s OxyChem Deal Signals Shift Toward Operating Assets And Buybacks

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE.

• Berkshire Hathaway (NYSE:BRK.A) is acquiring Occidental Petroleum’s OxyChem unit, expanding further into industrial and chemicals alongside its established energy holdings.

• The deal follows a rally in chemical stocks, as well as Occidental’s recent balance sheet improvements and dividend increase.

• Under CEO Greg Abel, Berkshire is pairing this acquisition with ongoing share buybacks and a more concentrated set of core holdings.

The OxyChem purchase adds a new industrial pillar to Berkshire Hathaway’s portfolio at a time of sharp swings in oil and commodity prices. With the Class A share price around $740,000.0 and a 3 year return of 64.9% and 5 year return of 94.0%, Berkshire enters this deal from a position of financial strength. For investors, it is another example of the company using its balance sheet to acquire operating assets rather than simply accumulating cash.

The move also provides a clearer view of how Greg Abel is shaping capital allocation, combining selective acquisitions with buybacks and a tighter group of core holdings. While the long term impact of OxyChem on returns and risk is uncertain, the transaction is likely to influence how the market views Berkshire’s sector mix and its approach to commodity linked businesses.

Stay updated on the most important news stories for Berkshire Hathaway by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Berkshire Hathaway.

We’ve flagged 1 risk for Berkshire Hathaway. See which could impact your investment.

The OxyChem deal gives Berkshire a large, cash-generating operating asset in chemicals that sits between its existing energy exposure and its industrial businesses. For a group that ended 2025 with US$373.3b in cash and treasuries and has been a net seller of listed stocks for 13 straight quarters, this looks like a choice to swap excess liquidity for a hard asset tied to real production. It also tilts Berkshire a bit further toward energy-adjacent earnings at a time when its Chevron stake is sensitive to swings in crude prices and other holdings, such as Apple and consumer-facing businesses, have recently pressured the share price. Under Greg Abel, pairing this acquisition with resumed buybacks and a more concentrated equity portfolio suggests a clearer capital-allocation framework: fewer stock picks, more control of entire businesses, and a preference for operating cash flows over financial assets when valuations feel stretched.

• ⚠️ Earnings for Berkshire are forecast to decline by an average of 4.8% per year for the next 3 years, so adding another cyclical, commodity-linked asset via OxyChem could add volatility to results if chemical pricing weakens.

• ⚠️ Full year 2025 net income of US$66,968m compares with US$88,995m a year earlier, which may increase investor scrutiny on whether this acquisition and future deals improve underlying profitability rather than simply using up the large cash pile.

• 🎁 Berkshire is assessed as trading at good value compared to peers and its industry, and owning OxyChem outright gives it another source of operating cash that is not dependent on equity markets.

• 🎁 The shares are described as trading about 38% below one estimate of fair value, and management is choosing to both buy back stock and acquire OxyChem, which signals confidence in using capital across more than one opportunity set.

From here, you may want to watch how OxyChem’s earnings and cash flows show up in Berkshire’s industrial and energy results, and whether they smooth or amplify commodity swings that also affect holdings like Chevron and Occidental Petroleum. It is also worth tracking how actively Abel continues to trim non core equity positions while adding full control businesses, and how he balances cash between further acquisitions, buybacks and the existing US$373.3b reserve. Finally, keep an eye on commentary around forecast earnings pressure and whether management ties any improvement to integration of OxyChem and other operating units.

To ensure you’re always in the loop on how the latest news impacts the investment narrative for Berkshire Hathaway, head to the community page for Berkshire Hathaway to never miss an update on the top community narratives.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include BRK-A.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com